Vitamin D3 supplementation, low-risk prostate cancer, and health disparities

被引:26
作者
Hollis, Bruce W. [1 ]
Marshall, David T. [2 ]
Savage, Stephen J. [3 ,6 ]
Garrett-Mayer, Elizabeth [4 ]
Kindy, Mark S. [5 ,6 ]
Gattoni-Celli, Sebastiano [2 ,6 ]
机构
[1] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA
[3] Med Univ S Carolina, Dept Urol, Charleston, SC 29425 USA
[4] Med Univ S Carolina, Dept Med Biostat, Charleston, SC 29425 USA
[5] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA
[6] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA
关键词
Vitamin D; Prostate cancer; Biopsy; Health disparities; 1,25-DIHYDROXYVITAMIN D-3; CONSERVATIVE MANAGEMENT; AFRICAN-AMERICAN; WHITE MEN; GROWTH; CELLS; IDENTIFICATION; EXPRESSION; GENE; PREVALENCE;
D O I
10.1016/j.jsbmb.2012.11.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vitamin D promotes the differentiation of prostate cancer cells, raising the possibility that vitamin D deficiency over time may contribute to the progression from subclinical prostate cancer to clinical disease. Since low-risk prostate cancers are monitored over time in an effort to determine which progress into clinically important, more aggressive cancers, they provide an excellent model in which to study, over an extended period of time, the effects of enhancing vitamin D status and related changes in tumor progression. This is particularly relevant to African-American men, who exhibit a high prevalence of vitamin D deficiency as well as higher incidence of prostate cancer and higher mortality rates from prostate cancer than Caucasians. Our research team has recently completed an open-label clinical trial aimed at assessing the safety and potential efficacy of vitamin D-3 supplementation at 4000 international units (IU) per day for one year in subjects diagnosed with early stage, low-risk prostate cancer. The results of this clinical study suggest that supplementation with vitamin D-3 at 4000 IU per day may benefit patients with early stage, low-risk prostate cancer on active surveillance, because of the improved outcome (a decreased number of positive cores at repeat biopsy) in more than half of the subjects enrolled in the trial. We also observed that, after one year of supplementation, there was no difference in circulating levels of vitamin D between African-American and Caucasian subjects who completed the study. These clinical results also suggest that robust and sustained vitamin D-3 supplementation can reduce prostate cancer-related health disparities in African-American men and that these health disparities are at least in part the result of widespread hypovitaminosis D within the African-American population. This article is part of a Special Issue entitled 'Vitamin D Workshop'.
引用
收藏
页码:233 / 237
页数:5
相关论文
共 45 条
  • [1] 20-year outcomes following conservative management of clinically localized prostate cancer
    Albertsen, PC
    Hanley, JA
    Fine, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17): : 2095 - 2101
  • [2] Mortality Results from a Randomized Prostate-Cancer Screening Trial
    Andriole, Gerald L.
    Grubb, Robert L., III
    Buys, Saundra S.
    Chia, David
    Church, Timothy R.
    Fouad, Mona N.
    Gelmann, Edward P.
    Kvale, Paul A.
    Reding, Douglas J.
    Weissfeld, Joel L.
    Yokochi, Lance A.
    Crawford, E. David
    O'Brien, Barbara
    Clapp, Jonathan D.
    Rathmell, Joshua M.
    Riley, Thomas L.
    Hayes, Richard B.
    Kramer, Barnett S.
    Izmirlian, Grant
    Miller, Anthony B.
    Pinsky, Paul F.
    Prorok, Philip C.
    Gohagan, John K.
    Berg, Christine D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (13) : 1310 - 1319
  • [3] 1α, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis
    Bao, Bo-Ying
    Yao, Jorge
    Lee, Yi-Fen
    [J]. CARCINOGENESIS, 2006, 27 (09) : 1883 - 1893
  • [4] 1α,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases
    Bao, BY
    Yeh, SD
    Lee, YF
    [J]. CARCINOGENESIS, 2006, 27 (01) : 32 - 42
  • [5] Barreto AM, 2000, CANCER EPIDEM BIOMAR, V9, P265
  • [6] 1α,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells
    Ben-Shoshan, Moshe
    Amir, Sharon
    Dang, Duyen T.
    Dang, Long H.
    Weisman, Yosef
    Mabjeesh, Nicola J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (04) : 1433 - 1439
  • [7] Expectant management of prostate cancer with curative intent: An update of the Johns Hopkins experience
    Carter, H. Ballentine
    Kettermann, Anna
    Warlick, Christopher
    Metter, E. Jeffrey
    Landis, Patricia
    Walsh, Patrick C.
    Epstein, Jonathan I.
    [J]. JOURNAL OF UROLOGY, 2007, 178 (06) : 2359 - 2364
  • [8] Prostate cancers in men with low PSA levels - Must we find them?
    Carter, HB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (22) : 2292 - 2294
  • [9] Prostatic 25-hydroxyvitamin D-1α-hydroxylase and its implication in prostate cancer
    Chen, TC
    Wang, LL
    Whitlatch, LW
    Flanagan, JN
    Holick, MF
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 88 (02) : 315 - 322
  • [10] CLEMENS TL, 1982, LANCET, V1, P74